Core Viewpoint - The article discusses the approval of four innovative medical devices by the National Medical Products Administration of China, highlighting advancements in medical technology and the companies behind these innovations [2]. Group 1: Innovative Medical Devices - The first approved product is a CT image-assisted triage software for pancreatic lesions, developed by Alibaba DAMO Academy, which focuses on AI and medical imaging technologies [5][6]. - The second product is a neurosurgical navigation system from Beijing United Imaging Healthcare Co., which aims to enhance clinical applications in prevention, diagnosis, treatment, and rehabilitation [7]. - The third product is a thrombectomy catheter developed by Zhejiang Guichuang Medical Technology Co., specializing in neurovascular and peripheral vascular interventional medical devices [8]. - The fourth product is an OCT image-assisted diagnostic software for retinal diseases, created by TuPai (Beijing) Medical Technology Co., which focuses on high-end ophthalmic medical equipment [9][10]. Group 2: Companies Overview - Alibaba DAMO Academy was established in November 2017 and is dedicated to scientific research and technological innovation, particularly in AI and medical imaging [6]. - Beijing United Imaging Healthcare Co. is part of the United Imaging Medical Technology Group and focuses on providing innovative medical products and solutions for clinical applications [7]. - Zhejiang Guichuang Medical Technology Co. has a history dating back to 2012 and specializes in the development and manufacturing of interventional medical devices for acute ischemic stroke and other conditions [8]. - TuPai (Beijing) Medical Technology Co. was founded in 2017 and is known for its advanced ophthalmic medical devices, leveraging research from Tsinghua University [10].

Core Insights - The China Securities Medical and Medical Device Innovation Index (931484) has seen a slight increase of 0.31%, with notable gains from stocks such as Huitai Medical (+6.20%) and Yingke Medical (+4.17%) [1] - The National Medical Products Administration (NMPA) reported that in 2025, it received 457 applications for special approval of innovative medical devices, with 104 approved for special review and 26 out of 38 priority applications granted [1] Group 1: Market Performance - The Medical Innovation ETF (516820) rose by 0.28%, with the latest price at 0.36 yuan [1] - The top ten weighted stocks in the China Securities Medical and Medical Device Innovation Index account for 63.9% of the index, including companies like WuXi AppTec and Mindray Medical [2] Group 2: Investment Strategy - Huafu Securities emphasizes a continued focus on the pharmaceutical technology sector, highlighting three main areas for 2026: revenue and performance realization, unexpected business development outcomes, and cutting-edge technology platforms [2] - In the medical device sector, the focus is on inventory replenishment and bidding for surgical robots and endoscopes, as well as innovative consumables benefiting from centralized procurement [2] - The central economic work conference has indicated a shift towards domestic demand, suggesting that companies related to domestic medical needs may experience a turning point [2]

Core Insights - The Chinese innovative medical device sector is experiencing a resurgence, highlighted by the recent IPO of Beixin Life on the STAR Market, which saw its stock price surge by 183% on the first day of trading, reaching over 40 yuan compared to the issue price of 17.52 yuan [2] - The medical device industry in China is showing signs of recovery, with the financing amounts in the primary market for medical devices surpassing those of 2023 and 2024, returning to 2022 levels [2] - The strategic investor system on the STAR Market allows institutions to participate more actively, which may lead to a new trend in medical device investments [3] Market Dynamics - Innovative medical devices are attracting interest due to their potential for quicker cash flow compared to innovative drugs, which often face higher risks and longer paths to profitability [4] - New and recently listed companies in the medical device sector are experiencing higher premiums due to their rapid growth phases, while established companies are facing valuation corrections [5] - The optimization of the centralized procurement mechanism is benefiting innovative medical device companies by stabilizing prices and enhancing payment capabilities for differentiated products [6] Investment Trends - The secondary market is expected to resonate with the primary market, with the latter often leading the former by a few years [8] - Current investment interest in the secondary market is likely reflecting the focus of the primary market from three to four years ago, particularly in areas like artificial intelligence and cardiovascular interventions [9] - The overall investment environment for medical devices in China is stabilizing, although it may not return to the peak levels seen in 2021 [10] Future Outlook - The next hotspot in the medical device industry is expected to be international expansion, particularly for high-value complex products that can provide cost-effective solutions in foreign markets [14] - Sustainable internationalization of medical devices requires unique products and active participation in commercialization rather than relying on distributors [17] - China is becoming a significant player in the global innovative medical device landscape, with increasing interest from overseas investors and industry players [18]

Group 1 - The core announcement is that MicroPort Cardiac Rhythm Management (MicroPort) has received a favorable review from the National Medical Products Administration (NMPA) for its new generation implantable cardioverter-defibrillator (ICD) TILEN/EYLEN, which is expected to enter the innovative medical device special review process [1] - TILEN/EYLEN is anticipated to be the first domestically approved MRI-safe ICD with independent intellectual property rights, addressing a significant technological gap in the domestic market [1] - The device features automatic MRI functionality, remote follow-up capabilities using low-power Bluetooth technology, and an industry-leading lifespan, which collectively aim to enhance patient comfort, compliance, and reduce long-term economic burdens [1] Group 2 - Sudden Cardiac Death (SCD) is a major global cause of mortality, and ICDs have been proven to be the most effective preventive measure against SCD, restoring normal heart rhythm during life-threatening arrhythmias [2] - The PLATINIUM series ICD products have already received NMPA approval in September 2024, marking the first domestically approved ICD, thus providing more treatment options for SCD in China and promoting the local development and application of high-energy defibrillator devices [2] - The entry of TILEN/EYLEN into the NMPA green channel is expected to accelerate the domestic production process of MRI-safe ICDs [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 MicroPort CardioFlow Medtech Corporation 微創心通醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2160） 自願公告 — 植入式心律轉復除顫器進入 創新醫療器械特別審查程序 本公告乃由微創心通醫療科技有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願作出，以知會本公司股東及潛在投資者有關本集團最新業務和新 產品開發進展。 本公司董事會（「董事會」）欣然宣佈，近日，國家藥品監督管理局「NMPA」醫療 器械技術審評中心發佈《創新醫療器械特別審查申請審查結果公示（2026年第3 號）》，擬同意本集團旗下新一代植入式心律轉復除顫器（「ICD」）TILEN/EYLEN （泰然╱怡然）進入創新醫療器械特別審查程序（「NMPA綠色通道」）。據此， TILEN/EYLEN（泰然╱怡然）有望成為國內首款獲批的具備自主知識產權的 ...

Core Insights - The National Medical Products Administration (NMPA) has approved several innovative medical devices, including a first-of-its-kind disposable peripheral vascular thrombectomy catheter, which meets international advanced standards [1] - In 2025, the NMPA announced that 122 products entered the special approval process for innovative medical devices, nearly doubling from 2024 [1][8] - The Chinese innovative medical device sector is poised for a significant breakthrough, similar to the rise of innovative pharmaceuticals in recent years [2] Group 1: Innovative Medical Device Market Trends - The trend of innovative medical device business development (BD) in China is gaining momentum, with domestic companies increasingly collaborating with local innovative device firms and multinational corporations [3] - Major Chinese companies like Yuan Da Pharmaceutical have formed partnerships with various innovative device firms to expand their product lines [4] - Global giants such as Edwards Lifesciences and Johnson & Johnson are collaborating with Chinese innovative device companies, indicating a narrowing gap in innovation and quality [4] Group 2: Approval Statistics and Comparisons - In 2025, 72 innovative medical devices were approved through the special review process, marking a historical high and a continuous growth trend since 2019 [6] - The number of innovative medical devices entering the special review process in 2025 reached 122, a significant increase compared to previous years [8] - The number of second-class innovative medical devices approved by provincial regulatory bodies also saw a substantial increase, with 131 products entering the special approval process in 2025, up over 30% from 2024 [10] Group 3: Challenges and Future Outlook - Despite the progress, the innovative medical device sector faces challenges in replicating the success of innovative pharmaceuticals due to differences in commercialization and development logic [15][16] - The commercialization of innovative devices is more complex and requires ongoing validation in clinical settings, making it harder to achieve rapid market penetration [17] - To enhance the development of innovative medical devices, systemic adjustments are needed, including faster approval processes, supportive payment structures, and international standard recognition [18][19]

Core Viewpoint - North Chip Life Technology Co., Ltd. (stock code: 688712.SH) has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with a closing price of 49.64 yuan, representing a 183.33% increase, and a total market capitalization of 20.7 billion yuan [1]. Company Overview - North Chip Life focuses on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, with 17 approved and in-development products as of September 30, 2025 [1]. - The company aims to provide transformative solutions for cardiovascular disease diagnosis and treatment, covering five major product categories including IVUS and FFR systems [1]. Financial Performance - The company reported a cumulative loss of 686.41 million yuan as of June 30, 2025, indicating potential challenges in future cash dividends [2]. - From 2022 to 2024, the company experienced a total net loss of 473.40 million yuan, with revenues increasing from 92.45 million yuan in 2022 to 316.60 million yuan in 2024 [8][9]. Shareholding Structure - The company has no controlling shareholder, with the actual controller being Song Liang, who holds 16.15% of the shares directly and has significant influence over company decisions [2][3]. - Other shareholders are primarily financial investors who do not seek control of the company, supporting Song Liang's position as the actual controller [3]. Fundraising and Use of Proceeds - North Chip Life raised a total of 998.64 million yuan in its IPO, with a net amount of 898.89 million yuan after deducting issuance costs [5]. - The funds will be allocated to the construction of an interventional medical device industrialization base, R&D projects, and to supplement working capital, with a total planned investment of 952.21 million yuan [6][7]. Future Projections - For 2025, the company expects revenue between 520 million yuan and 560 million yuan, representing a growth of 64.24% to 76.88% year-over-year, and a net profit of 78 million yuan to 88 million yuan, indicating a growth of 278.91% to 301.85% [13].

Core Viewpoint - The National Medical Products Administration (NMPA) has approved 10 innovative medical devices for special review procedures as part of the third batch of applications for 2026 [1][2] Group 1: Approved Innovative Products - The following innovative products have been granted special review status: 1. Chronic Obstructive Pulmonary Disease Assessment Software by Bojiang Life Sciences (Shanghai) Co., Ltd. [1][2] 2. Ultrasound Therapy Device by Shenzhen Tengfu Medical Technology Co., Ltd. [1][2] 3. Transcatheter Artificial Tricuspid Valve by Edwards Lifesciences LLC [1][2] 4. Transcatheter Artificial Tricuspid Valve by Jiangsu Zhenyi Medical Technology Co., Ltd. [1][2] 5. Ultrasound Thrombolysis Catheter and Stent System by Shanghai Tengfu Medical Technology Co., Ltd. [1][2] 6. Radiation Therapy Planning Software by Guoke Ion Medical Technology Co., Ltd. [1][2] 7. Implantable Cardioverter Defibrillator by Chuangling Cardiac Rhythm Management Medical Device (Shanghai) Co., Ltd. [1][2] 8. Peripheral Balloon Expandable Stent System by Zhejiang Guichuang Medical Technology Co., Ltd. [1][2] 9. Thoracoabdominal Endoscopic Surgical System by Zhi Guan Medical Company [1][2] 10. Coronary Sinus Balloon Counterpulsation System by Shanghai Micron Melody Medical Technology Co., Ltd. [1][2]

Group 1 - The core viewpoint of the article highlights an unprecedented wave of IPO applications from over 13 medical device companies in China, marking a significant shift in the industry as multiple sectors prepare to launch their "first stocks" [2][3][4] - The medical device market in China is projected to reach 1.22 trillion yuan by 2025, reflecting a growth of approximately 30% from 941.7 billion yuan in 2024, indicating a robust market outlook [4][15] - The reactivation of the fifth listing standard on the STAR Market has lowered the barriers for high R&D investment companies, facilitating the entry of innovative firms that may not yet be profitable [3][15][20] Group 2 - The competition for the title of "first stock" in various segments is intensifying, with companies like Core Medical and Tongxin Medical vying for leadership in the artificial heart market [5][17] - Notable companies such as Jinjiang Electronics and Saiwei Technology are also advancing their IPO processes, with Jinjiang Electronics having launched China's first domestic cardiac mapping system [6][18] - The financing landscape is shifting, with total financing in the first half of 2025 increasing by 17.01% year-on-year to 16.695 billion yuan, indicating a trend towards concentrated investment in validated innovative enterprises [4][16] Group 3 - Despite the promising outlook, many innovative medical device companies face significant profitability challenges due to high R&D costs and long development cycles, with Core Medical reporting R&D expenditures of 119 million yuan, 151 million yuan, and 87.5 million yuan from 2023 to mid-2025 [8][20] - Companies are adjusting their pricing strategies to penetrate the market, with Core Medical's average sales price for its commercialized product dropping from 290,400 yuan in 2023 to 229,600 yuan in the first half of 2025 [9][21] - The IPO process is seen as a critical pathway for these companies to secure low-cost funding, advance clinical research, and expand production capabilities [9][22]

Core Viewpoint - The company, Beixin Life, is launching an IPO with 57 million shares at a price of 17.52 yuan per share, aiming to raise funds for the development of interventional medical devices and enhance its production capacity and R&D capabilities [1] Group 1: Company Overview - Beixin Life is recognized as a national-level "specialized and innovative" small giant enterprise and has been awarded the title of a provincial manufacturing champion in Guangdong for 2024 [1] - The company focuses on the research, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [1][2] - Beixin Life is the first domestic company to offer a combination of intravascular functional (FFR) and imaging (IVUS) products, addressing a significant gap in the domestic market and reducing reliance on imported products for coronary artery disease diagnosis [1][2] Group 2: Product Development and Market Position - The core product, the IVUS system, is the first domestically developed 60MHz high-definition IVUS product approved in China and the first to be approved for sale in Europe, achieving the highest market share among domestic brands [2] - The FFR system, launched in 2020, captured 30.6% of the domestic market share by 2021, contributing to rapid revenue growth for the company [3] - As of September 30, 2025, the company plans to have launched 11 products and has 6 products in development, covering five major categories including IVUS, FFR, vascular access products, shockwave balloon therapy systems, and electrophysiological solutions [2] Group 3: Financial Performance - The company's revenue has shown significant growth, with figures of 92.45 million yuan, 183.98 million yuan, and 316.60 million yuan for the years 2022, 2023, and 2024 respectively [3] - For 2025, the company projects revenue between 520 million yuan and 560 million yuan, representing a year-on-year growth of 64.24% to 76.88%, with net profit expected to be between 78 million yuan and 88 million yuan, indicating a growth of 278.91% to 301.85% [3]